NCT07322783 2026-01-07
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Qingdao Central Hospital
Phase 2 Recruiting
Clinical Trials
5 trialsNCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT06208033 2024-01-17
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT03126799 2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2 Unknown
NCT03382795 2021-07-15
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
Korea University Guro Hospital
Phase 2 Unknown